SEC Filing Summary: Landec Corporation (LNDC)
Business Context and Reporting Period
This Form 8-K was filed by Landec Corporation on August 8, 2019, reporting events that occurred on August 5, 2019. The filing addresses corporate governance changes and executive compensation. Note: While the request metadata mentions "LIFECORE BIOMEDICAL, INC.", the filing text identifies the registrant as Landec Corporation, with Lifecore Biomedical, Inc. mentioned only in the context of an executive officer's title.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters.
Material Changes and Corporate Actions
- Board Election: The Board of Directors elected Katrina Houde as a Class 1 Director effective August 5, 2019. Ms. Houde has no material interest in transactions exceeding $120,000 involving the Company since the beginning of the last fiscal year.
- Executive Compensation: The Board approved the grant of 10,000 restricted stock units (RSUs) to James G. Hall, President of Lifecore Biomedical, Inc. These RSUs are scheduled to vest on the third anniversary of the grant date.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. No unusual items were reported.
Investor Verification Checklist
- Verify the professional background and qualifications of the newly elected director, Katrina Houde.
- Confirm the vesting schedule and fair value of the 10,000 RSUs granted to James G. Hall.
- Review the relationship between Landec Corporation and Lifecore Biomedical, Inc., given the executive title referenced in the compensation grant.